Document ID: chunk:federal_register_of_legislation:F2024C01228:front:0:p12
Version: federal_register_of_legislation:F2024C01228
Segment Type: other
Provision Reference: 
Character Range: 29640–31398

factor inhibitors;
                    (B) T‑cell co‑stimulation modulators such as Abatacept);
                    (C) soluble TNF receptors;
                    (D) type I interferon receptor inhibitors;
                    (E) proteasome inhibitors;
                    (F) IL inhibitors currently or within the last 6 months, including anti‑IL1 antibodies, anti‑IL4/13 antibodies, anti‑IL5 antibodies, anti‑IL6 antibodies, IL‑6 receptor inhibitors;

            (vii) immunomodulatory drugs including sphingosine‑1‑phosphate receptor modulators within the last 6 months;
            (viii) oral small molecule targeted therapies, received currently or within the last 6 months including any of the following:
                    (A) bruton's tyrosine kinase inhibitors;
                    (B) janus kinase inhibitors;
                    (C) BCR‑ABL inhibitors.
Schedule 1 Designated vaccines and circumstances in which vaccines may be provided
(sections 5 and 6)
Part 1 Bacterial vaccines
Item  Vaccine and the circumstances in which vaccine may be provided                                                                                                                                                                                                                         Brand              Formulation                                                                       Active ingredient and strength                                                                                                                                                                                                                                                                                                                                 Number and timing of doses